Asset Details
Do you wish to reserve the book?
Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
Do you wish to request the book?
Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
2020
Overview
Aims As an extension of a phase 2/3 study evaluating the efficacy and safety of lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/d for 4 weeks in Japanese patients aged 6‐17 years with attention‐deficit/hyperactivity disorder (ADHD), this study evaluated its long‐term safety and efficacy. Methods This was a multicenter, open‐label study of LDX for 53 weeks. Safety was assessed by regular medical examination for treatment‐emergent adverse events (TEAEs); regular recording of body weight, vital signs, and laboratory test values; and completion of dependence questionnaires. Efficacy was assessed using Japanese versions of the ADHD‐Rating Scale‐IV (ADHD‐RS‐IV) and Conners' 3rd edition Parent Rating Scale (Conners 3); plus Clinical Global Impression‐Improvement (CGI‐I), Clinical Global Impression‐Severity, and Parent Global Assessment (PGA) scales. Results Of 132 enrolled patients, 104 completed the trial. Most frequent treatment‐related TEAEs were decreased appetite (73.5%), initial insomnia (39.4%), and weight decrease (22.0%). Most TEAEs were mild (82.6% of patients). There were no serious or severe TEAEs or deaths. No treatment‐related TEAEs were associated with blood pressure or pulse rate, and no patient had a QTcF interval >500 ms. Statistically significant improvement from baseline to week 53 was observed in the mean ADHD‐Rating Scale‐IV total score and mean Conners 3 subscale scores. Most patients showed improvement on the CGI‐I (78%) and PGA (76.5%) scales. Conclusions No significant safety issues were observed with LDX 30, 50, or 70 mg/d administered for 1 year in Japanese children and adolescents with ADHD. LDX was associated with long‐term reductions in ADHD symptoms and severity. This multicenter, open‐label study evaluated the long‐term safety and efficacy of lisdexamfetamine dimesylate (LDX) in Japanese patients aged 6‐17 years with attention‐deficit/hyperactivity disorder. No significant safety issues were observed with LDX 30, 50, or 70 mg/d administered for 1 year. There were no serious or severe treatment‐emergent adverse events (TEAEs) or deaths. The most frequent treatment‐related TEAEs were decreased appetite, initial insomnia, and weight decrease. TEAEs were mild in 82.6% of patients.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
